OSI-461 (OSI).

Abstract

OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461.

• Authors: Carlos M Galmarini
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 6 Pg. 648-56 (Jun 2004) ISSN: 1472-4472 [Print] England
• PMID: 15242254 (Publication Type: Journal Article, Review)

Chemical References

• (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride
• Antineoplastic Agents
• Drugs, Investigational
• Phosphodiesterase Inhibitors
• Sulindac

Topics

• Animals
• Antineoplastic Agents (adverse effects, chemistry, pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Drugs, Investigational (adverse effects, chemistry, pharmacology, therapeutic use)
• Humans
• Inflammatory Bowel Diseases (drug therapy, metabolism)
• Neoplasms (drug therapy, metabolism)
• Phosphodiesterase Inhibitors (chemistry, pharmacology, therapeutic use)
• Sulindac (adverse effects, analogs & derivatives, chemistry, pharmacology, therapeutic use)